Camber Specialty Capabilities
In 2022, Hetero and Camber Pharmaceuticals established Camber Specialty in response to the growing demand for high-quality, low-cost specialty medications supporting hospitals, clinics, oncology treatment centers, government, and other institutional customers.
Learn more about Camber Specialty in this short video.
Recent articles
- Buprenorphine and Naloxone Sublingual Tablets Added to Portfolio
- New to Camber’s Portfolio: Losartan Potassium and Hydrochlorothiazide Tablets
- NACDS TSE 2026 Event Recap
- Camber Specialty Marks First Day 1 Injectable Launch
- New to Camber’s Portfolio: Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets
- Camber Pharmaceuticals Honored as Second Merit Finalist at 2026 DIANA Awards